查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856758

次世代定序仪CLIA实验室服务市场（按服务类型、应用、最终用户、技术平台和样本类型划分）—全球预测，2025-2032年

Next Generation Sequencing CLIA Laboratory Services Market by Service Type, Application, End User, Technology Platform, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，次世代定序仪CLIA 实验室服务市场将成长至 192.1 亿美元，复合年增长率为 13.89%。

主要市场统计数据
基准年 2024 67.8亿美元
预计年份：2025年 77.1亿美元
预测年份：2032年 192.1亿美元
复合年增长率 (%) 13.89%

本书对塑造CLIA认证的下一代定序实验室服务的商业实践和策略要务进行了引人入胜的介绍。

随着新一代定序 (NGS) 方法日益融入常规临床工作流程，临床分子诊断领域正进入加速成熟阶段。本执行摘要全面而实用地阐述了 CLIA 认证的 NGS化验服务的演变历程、将再形成服务交付模式的曲折点，以及领导者为保持竞争力必须考虑的战略选择。本文建构了临床EXOME、标靶基因panel和全基因组策略与不断变化的支付方预期、日益严格的监管审查以及对精准医疗日益增长的需求并存的商业格局。

前瞻性地整合技术、监管和营运方面的变革，重新定义临床下一代定序服务的交付和伙伴关係。

在多种因素的共同推动下，CLIA化验服务与新一代定序技术的整合正经历着一场变革。技术进步降低了高效能定序的门槛，同时也增加了分析的复杂性，迫使实验室快速迭代检测设计、验证框架和资讯学流程。新的定序平台和改进的化学方法正在改变人们对通量经济性和数据品质的考量，导致临床检测的选择面临许多挑战，例如靶向panel、EXOME组测序和全基因组检测。

对近期关税调整将如何重塑临床NGS实验室的采购韧性、业务连续性和供应商策略进行深入分析

美国将于2025年实施新的关税，将对依赖全球供应链的CLIA认证的下一代定序实验室产生即时且连锁的影响。进口试剂、耗材和仪器零件的关税将增加单位成本，并使长期采购计画更加复杂。先前已根据可预测的供应商价格优化成本结构的实验室，需要评估其成本基础对关税波动的敏感性，并考虑避险策略、多供应商采购和近岸外包等措施来降低风险。

深入分析决定服务类型、临床用途、最终用户、平台技术以及操作和解读复杂性的样本考虑因素。

深入的细分揭示了不同服务类型、应用、最终用户、技术平台和样本类型在临床价值和操作复杂性方面的差异。不同的服务类型—临床EXOME定序、标靶基因panel检测和全基因定序—展现出不同的验证负担和临床报告要求。临床EXOME序分为成人和EXOME，需要专门的解读流程以及不同的知情同意和变异註释实践；而靶向基因panel检测，例如癌症、心血管疾病和神经系统疾病panel检测，则提供了以临床效用为重点的可扩展渠道。在癌症panel检测中，血液肿瘤panel和固体癌panel之间的区别决定了检体处理要求和生物资讯学工作流程的差异，这要求实验室明确满足这些需求。

对世界主要地区临床基因组学服务的监管细微差别、采购动态和招募管道进行区域分析

在美洲、中东和非洲以及亚太地区，地域动态持续影响定序平台的取得、试剂供应链、监管解读和临床应用率，从而为各地区的实验室制定了不同的策略重点。在美洲，综合医疗体系和先进的肿瘤治疗中心推动了对伴随诊断和复杂测序服务的需求，而法规环境则侧重于CLIA认证和与支付方的合作，以实现临床认可和规模化应用。

深入分析决定临床定序服务竞争优势的供应商定位、整合解决方案策略和伙伴关係模式

主要企业之间的竞争动态取决于其技术组合的广度、全球生产和供应的韧性、试剂和耗材生态系统，以及生物资讯学和临床报告支援的深度。领先的定序平台供应商不仅在读取准确性和通量方面展开竞争，还在下游服务方面竞争，例如检测试剂盒、参考资料资料库和整合资讯学，这些服务能够缩短临床验证的时间并降低成本。平台供应商与诊断实验室之间的策略伙伴关係，透过将验证路径与供应保障相结合，正在加速检测方法的普及应用。同时，投资于试剂可靠性和​​本地化生产的企业将在供应紧张时期获得营运优势。

针对实验室主管，制定可操作的策略重点，重点在于采购弹性、临床差异化和可扩展的卓越营运。

产业领导者必须采取双管齐下的策略，在短期营运韧性和长期临床差异化之间取得平衡。首先，优先考虑供应商多元化和长期合约安排，以抵御供应链不稳定和关税的影响。这包括评估替代供应商、建立本地製造伙伴关係以及製定能够维持临床连续性的库存策略。其次，投资于模组化自动化和标准化品质体系，以加快检测验证速度、降低错误率并支持可扩展的通量，同时确保临床解读的严谨性。

采用透明的调查方法，结合主要相关人员访谈、技术检验审查和情境压力测试，以提供可操作的实用见解。

本研究结合了实验室负责人、平台供应商、临床相关人员和相关领域专家的访谈，以及对监管指南、同行评审文献和供应商技术文件的系统性回顾，从而提供全面且可操作的评估。调查方法强调三角验证：定性访谈提供营运方面的见解，技术检验和方案审查揭示检测性能的限制，平台规格的比较分析揭示与临床部署相关的权衡取舍。

总结性报告重点阐述了策略执行、供应商韧性和临床证据管道如何帮助临床基因组医学服务的持续成长。

总而言之，CLIA认证的下一代定序实验室服务正处于曲折点，技术进步、供应链动态、监管预期以及临床应用模式的转变既带来了挑战，也带来了机会。那些积极提升采购韧性、投资强大的生物资讯学解读框架、并与平台供应商和临床相关人员建立伙伴关係的实验室，更有能力将技术能力转化为可靠且具有临床应用价值的服务。标靶基因组定序、EXOME序和全基因组定序之间的相互作用，需要一种能够将检测方法的选择与临床效用、运作能力和监管要求相匹配的综合思维。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合自动化和人工智慧驱动的生物资讯流程，用于高效能临床定序
  • 利用液态切片扩大NGS检测规模，实现肿瘤微量残存疾病的即时监测
  • 在不同人群中实施药物基因组学NGS检测以实现个人化药物治疗管理
  • 采用长读长定序技术提高遗传疾病诊断中结构变异的侦测率
  • 开发快速的样本到报告NGS工作流程，以支持突发感染疾病疫情应对
  • CLIA 合规参考物质的标准化和实验室间 NGS 检测验证的能力验证

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章次世代定序仪CLIA 实验室服务市场（依服务类型划分）

  • 临床EXOME定序
    • 成人外EXOME
    • 儿科外EXOME
  • 标靶基因检测
    • 癌症小组
      • 血液学检查
      • 固态肿瘤组
    • 心血管专家组
    • 神经系统疾病专家小组
  • 全基因组定序

第九章次世代定序仪CLIA 实验室服务市场（依应用划分）

  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 遗传性疾病
    • 一般疾病
    • 罕见疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固态肿瘤
  • 药物基因体学
  • 生殖医学
    • 非侵入性产前检测
    • 胚胎着床前遗传学检测

第十章次世代定序仪CLIA 实验室服务市场（依最终用户划分）

  • 诊断实验室
  • 直接面向消费者的测试
  • 医院诊所
  • 研究所

第十一章次世代定序仪CLIA实验室服务市场（依技术平台划分）

  • 华大基因定序平台
    • Bgiseq 500
    • Mgiseq
  • Illumina定序平台
    • MiSeq
    • NextSeq
    • NovaSeq
  • Thermo Fisher定序平台
    • 离子激流 PGM
    • 离子洪流质子

第十二章次世代定序仪CLIA 实验室服务市场（依样本类型划分）

  • 血
    • 电浆
    • 全血
  • 唾液
  • 组织
    • FFPE
    • 新鲜冷冻

第十三章次世代定序仪CLIA 实验室服务市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章次世代定序仪CLIA 实验室服务市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国次世代定序仪CLIA实验室服务市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Foundation Medicine, Inc.
    • Illumina Clinical Services Laboratory, Inc.
    • Natera, Inc.
    • Myriad Genetics, Inc.
    • Fulgent Genetics, Inc.
    • Guardant Health, Inc.
    • Invitae Corporation
    • Veracyte, Inc.
    • Personalis, Inc.
    • Adaptive BIoTechnologies Corporation
Product Code: MRR-C41945B3D381

The Next Generation Sequencing CLIA Laboratory Services Market is projected to grow by USD 19.21 billion at a CAGR of 13.89% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.78 billion
Estimated Year [2025] USD 7.71 billion
Forecast Year [2032] USD 19.21 billion
CAGR (%) 13.89%

A compelling introduction to the operational realities and strategic imperatives reshaping CLIA-certified next generation sequencing laboratory services

The clinical molecular diagnostics landscape is entering a phase of accelerated maturation where next generation sequencing (NGS) methodologies are increasingly embedded in routine clinical workflows. This executive summary introduces a comprehensive and pragmatic view of how CLIA-certified NGS laboratory services are evolving, the technology and operational inflection points reshaping service delivery, and the strategic choices leaders must deliberate to remain competitive. It frames the business context in which clinical exome, targeted gene panels, and whole genome strategies coexist alongside shifting payer expectations, tighter regulatory scrutiny, and rising demand for precision therapeutics.

Transitioning from development to clinical scale requires an integrated perspective that spans technology platform selection, sample logistics, bioinformatics pipelines, and quality management systems. The Introductory section therefore situates readers within the operational realities of accredited laboratories, highlighting how end users-from hospitals to direct-to-consumer channels-are changing requisition patterns and expectations for turnaround, interpretive clarity, and clinical utility. By focusing on pragmatic change drivers rather than abstract projections, this section prepares decision-makers to interpret subsequent insights and to prioritize investments that yield measurable clinical and commercial returns.

A forward-looking synthesis of technological, regulatory, and operational shifts redefining clinical next generation sequencing service delivery and partnerships

The landscape for CLIA laboratory services powered by next generation sequencing is undergoing transformative shifts driven by several converging forces. Technological progress is lowering the barrier to high-throughput sequencing while simultaneously increasing analytical complexity, compelling laboratories to iterate rapidly on assay design, validation frameworks, and informatics pipelines. Newer sequencing platforms and chemistry refinements are changing throughput economics and data quality considerations, which in turn affect clinical assay choices between targeted panels, exome approaches, and whole genome testing.

Alongside technology, regulatory and reimbursement environments are evolving. Laboratories are adapting to more stringent validation expectations, transparency around variant interpretation, and the need for robust clinical evidence to support diagnostic claims. Payer policies are increasingly focused on demonstrable clinical utility and value-based outcomes, prompting laboratories to emphasize assay standardization, clinical reporting consistency, and longitudinal data collection. Concurrently, the rise of precision oncology and the integration of genomic data into electronic health records are driving tighter collaboration between diagnostic providers, hospitals, and therapeutics developers, creating new service models such as companion diagnostics and longitudinal genomic surveillance.

Operationally, workforce constraints and the need for specialized bioinformatics expertise are catalyzing partnerships with external data providers and software vendors, while quality accreditation and scalability considerations drive laboratories to invest in automation, laboratory information management systems, and cloud-enabled pipelines. Taken together, these shifts mandate a strategic balancing act: adopting innovations that deliver clinical differentiation while ensuring compliance, cost control, and reproducibility in high-volume, regulated environments.

A rigorous analysis of how recent tariff adjustments reshape procurement resilience, operational continuity, and supplier strategies for clinical NGS laboratories

The implementation of new tariff measures in the United States in 2025 introduces immediate and cascading implications for CLIA-certified next generation sequencing laboratories that rely on global supply chains. Tariffs on imported reagents, consumables, and equipment components increase unit costs and complicate long-term procurement planning. Laboratories that previously optimized cost structures around predictable vendor pricing must now evaluate the sensitivity of their cost base to duty fluctuations and consider hedging strategies, multi-sourcing, or nearshoring to mitigate exposure.

Supply chain disruptions are another direct consequence, with extended lead times and allocation risks prompting laboratory managers to reassess inventory policies, safety stock levels, and supplier contracts. In certain instances, laboratories may face prioritization dilemmas when critical reagents or platform components become constrained, forcing a re-evaluation of test menus, throughput commitments, and clinical prioritization frameworks. These operational trade-offs have implications for turnaround time commitments and customer relationships, particularly for high-acuity services such as oncology panels and prenatal diagnostics.

The tariff environment also reshapes competitive positioning. Vendors with diversified manufacturing footprints or domestic production capabilities gain relative advantage, while smaller suppliers dependent on cross-border supply chains may experience margin compression or exit pressures. For laboratories, this means procurement strategies must increasingly incorporate supplier resilience metrics and total landed cost analyses rather than purely unit price comparisons. Additionally, the tariff context incentivizes collaborative approaches with sequencing platform manufacturers and reagent suppliers to secure long-term supply agreements, co-developed pricing models, or localized manufacturing arrangements that preserve service continuity and cost predictability.

Regulatory and compliance frameworks intersect with tariffs in nuanced ways. Changes to import regimes can affect lead times for validated components, necessitating revalidation efforts where alternates or substitute reagents are introduced. Laboratories must therefore build flexible validation pathways and ramp testing protocols that allow controlled substitution without compromising clinical integrity. In sum, the 2025 tariff adjustments force a strategic reorientation across procurement, operations, quality assurance, and commercial engagement to sustain service reliability and maintain margins under greater supply-chain volatility.

A granular exploration of service type, clinical application, end user, platform technology, and sample considerations that determine operational and interpretive complexity

Insightful segmentation illuminates where clinical value and operational complexity intersect across service type, application, end user, technology platform, and sample type. Service type distinctions among clinical exome sequencing, targeted gene panel testing, and whole genome sequencing reveal different validation burdens and clinical reporting demands; clinical exome efforts split between adult and pediatric exomes require specialized interpretive pipelines and distinct consent and variant curation practices, while targeted gene panels such as cancer, cardiovascular, and neurological disorder panels present scalable pathways for focused clinical utility. Within cancer panels, the distinction between hematologic panels and solid tumor panels creates divergent specimen processing requirements and bioinformatics workflows that laboratories must explicitly address.

Application-level segmentation underscores varied clinical evidence needs and specimen workflows. Infectious disease testing divides into bacterial and viral workflows with unique nucleic acid extraction and contamination control considerations, whereas inherited disease testing spans common conditions suitable for higher-throughput approaches and rare disease analyses that demand deep variant curation and multidisciplinary case review. Oncology applications bifurcate into hematologic malignancies and solid tumors, each with differing tissue handling demands and variant interpretation frameworks. Reproductive health applications, ranging from noninvasive prenatal testing to preimplantation genetic testing, impose stringent pre-analytic controls and counseling pathways that laboratories must operationalize.

End user segmentation differentiates service delivery models and commercial interfaces. Diagnostic laboratories, direct-to-consumer testing channels, hospitals and clinics, and research institutes each present unique requisition workflows, reporting expectations, and compliance obligations, requiring laboratories to calibrate client service models accordingly. Technology platform choices among BGI, Illumina, and Thermo Fisher sequencing platforms necessitate vendor-specific validation strategies and throughput planning; within these families, instrument variants such as Bgiseq 500, Mgiseq, MiSeq, NextSeq, NovaSeq, and Ion Torrent models introduce discrete technical and logistical considerations. Sample type segmentation across blood, saliva, and tissue embodies divergent pre-analytic and storage needs, where blood subsets like plasma versus whole blood and tissue formats such as FFPE versus fresh frozen demand tailored extraction and quality assessment procedures. Collectively, these layered segments define the operational playbook laboratories must design to ensure assay reliability, interpretive clarity, and fit-for-purpose clinical deployment.

A regional analysis of regulatory nuance, procurement dynamics, and adoption pathways shaping clinical genomic services across major global regions

Geographic dynamics continue to shape access to sequencing platforms, reagent supply chains, regulatory interpretations, and clinical adoption rates across the Americas, Europe Middle East & Africa, and Asia-Pacific, creating differentiated strategic priorities for laboratories operating in each region. In the Americas, integrated health systems and pockets of advanced oncology care drive demand for companion diagnostics and high-complexity sequencing services, while the regulatory environment emphasizes CLIA accreditation and payer engagement to achieve clinical acceptance and scaling.

Across Europe, the Middle East and Africa, heterogeneity in regulatory frameworks and reimbursement policies generates a patchwork market where laboratories must navigate divergent national requirements and data protection regimes. This environment favors flexible service models, partnerships with regional reference labs, and investments in localized clinical evidence to support adoption. In the Asia-Pacific region, rapid platform uptake, significant local manufacturing presence, and ambitious public health sequencing initiatives are catalyzing growth, but laboratories must manage complex logistics, multilingual reporting requirements, and variable reimbursement mechanisms to translate capability into sustainable clinical services.

The regional differences also influence talent availability, automation adoption, and laboratory consolidation trends. Markets with constrained skilled bioinformatics and clinical genetics capacity often rely more heavily on centralized reference labs or cloud-based interpretive services, whereas regions with concentrated specialist centers can support decentralized offerings and closer hospital-laboratory integration. Understanding regional regulatory nuances, procurement cycles, and clinical referral patterns enables laboratories to tailor go-to-market strategies that align with local demand signals and operational realities.

An in-depth look at vendor positioning, integrated solution strategies, and partnership models that determine competitive advantage in clinical sequencing services

Competitive dynamics among key companies are defined by technology portfolio breadth, global manufacturing and supply resilience, reagent and consumable ecosystems, and the depth of bioinformatics and clinical reporting support. Leading sequencing platform providers compete not only on read accuracy and throughput but also on downstream services such as assay kits, reference databases, and integrated informatics offerings that reduce the time and cost to clinical validation. Strategic partnerships between platform vendors and diagnostic laboratories accelerate assay adoption by aligning validation pathways and supply assurances, while companies investing in reagent reliability and localized production gain operational advantages under constrained supply conditions.

In parallel, companies that offer integrated solutions encompassing sample-to-report workflows, regulatory support, and clinician-facing interpretive tools are increasingly valued by laboratories seeking to shorten deployment timelines and minimize internal development overhead. The emergence of specialized players delivering curated variant databases, clinical decision support, and regulatory-ready documentation creates an ecosystem where laboratories can assemble best-of-breed components or adopt end-to-end solutions depending on strategic priorities. Competitive differentiation also arises from services tailored to high-value clinical applications such as oncology and reproductive health, where the ability to demonstrate clinical validity, report clarity, and actionable recommendations influences purchasing and referral decisions.

Finally, nimble vendors that provide flexible commercial models-subscription-based informatics, reagent-as-a-service, or collaborative validation programs-are well-positioned to support laboratories through technology transitions and regulatory change. As consolidation and strategic alliances continue, laboratories should evaluate partners based on technical performance, supply chain resilience, and the capacity to co-develop clinical workflows that align with institutional objectives.

Actionable strategic priorities for laboratory executives focused on procurement resilience, clinical differentiation, and scalable operational excellence

Industry leaders must pursue a dual strategy that balances near-term operational resilience with long-term clinical differentiation. First, prioritize supplier diversification and long-term contractual arrangements to protect against supply chain volatility and tariff impacts; this includes evaluating alternative vendors, localized manufacturing partnerships, and inventory strategies that preserve clinical continuity. Second, invest in modular automation and standardized quality systems that accelerate assay validation, reduce error rates, and support scalable throughput without sacrificing clinical interpretive rigor.

Third, strengthen bioinformatics and variant interpretation capabilities through a combination of internal talent development and external partnerships, ensuring reproducible pipelines, transparent curation policies, and clinician-friendly reporting. Fourth, deepen engagement with payers and clinicians to build evidence of clinical utility and pathway integration, focusing on high-impact applications such as oncology panels and reproductive health testing where diagnostic decisions directly inform care. Fifth, adopt flexible commercial models and customer support offerings that align with different end-user expectations-from hospitals requiring integrated EHR reporting to direct-to-consumer channels seeking simplified results and counseling frameworks.

Finally, embed regulatory foresight into strategic planning by cultivating capabilities for rapid revalidation, documentation management, and audit readiness. Leaders should also consider collaborative approaches with platform vendors and peer laboratories to share validation burden, harmonize reporting standards, and accelerate adoption of best practices. These combined actions will enable organizations to preserve service reliability, enhance clinical credibility, and capture opportunities created by evolving care pathways and technology advances.

A transparent methodology combining primary stakeholder interviews, technical validation review, and scenario stress-testing to inform operationally actionable insights

This research synthesizes primary engagements with laboratory leaders, platform vendors, clinical stakeholders, and subject-matter experts, combined with systematic review of regulatory guidance, peer-reviewed literature, and vendor technical documentation to produce a comprehensive and practical assessment. The methodology emphasizes triangulation: qualitative interviews contextualize operational realities, technical validations and protocol reviews illuminate assay performance constraints, and comparative analyses of platform specifications identify trade-offs relevant to clinical deployment.

Quality assurance in the research process included cross-validation of interpretive frameworks with practicing clinical geneticists and laboratory directors, and scenario stress-testing of procurement and supply-chain responses to tariff changes. The research also incorporated detailed mapping of sample workflows across specimen types-blood, saliva, and tissue-to identify pre-analytic vulnerabilities and mitigation strategies. Where possible, evidence was prioritized that reflects clinical workflows and regulatory compliance needs rather than marketing claims, ensuring that recommendations are implementable and aligned with accreditation requirements.

Analytical approaches focused on decomposing operational costs into process-level activities, evaluating validation timelines for different assay classes, and assessing vendor resilience across manufacturing footprints. Throughout, confidentiality and ethical considerations guided primary data collection, and methodologies were designed to be transparent and reproducible so that organizations can adapt the approach for their internal audits and strategic planning exercises.

A conclusive synthesis emphasizing strategic execution, supplier resilience, and clinical evidence pathways that enable sustainable growth in clinical genomics services

In conclusion, CLIA-certified next generation sequencing laboratory services are at an inflection point where technology advances, supply-chain dynamics, regulatory expectations, and shifting clinical adoption patterns converge to create both challenges and opportunities. Laboratories that proactively address procurement resilience, invest in robust bioinformatics and interpretive frameworks, and cultivate partnerships with platform vendors and clinical stakeholders will be best positioned to translate technological capability into reliable, clinically actionable services. The interplay between targeted panels, exome approaches, and whole genome testing requires a portfolio mindset that aligns assay choice with clinical utility, operational capacity, and regulatory obligations.

Furthermore, regional dynamics and tariff-related supply risks underscore the necessity for flexible validation pathways and diversified sourcing strategies. Companies and laboratories that prioritize quality systems, clinician engagement, and payer evidence-building can accelerate adoption while maintaining compliance and trust. Ultimately, success in this sector will hinge on disciplined execution across laboratory processes, strategic supplier relationships, and a relentless focus on delivering clear clinical value that integrates seamlessly into patient care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of automation and AI-driven bioinformatics pipelines for high throughput clinical sequencing
  • 5.2. Expansion of liquid biopsy-based NGS assays for real-time monitoring of minimal residual disease in oncology
  • 5.3. Implementation of pharmacogenomic NGS testing for personalized medication therapy management in diverse populations
  • 5.4. Adoption of long-read sequencing technologies to improve detection of structural variants in genetic disease diagnostics
  • 5.5. Development of rapid sample-to-report NGS workflows to support urgent infectious disease outbreak response
  • 5.6. Standardization of CLIA-compliant reference materials and proficiency testing for NGS assay validation across labs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next Generation Sequencing CLIA Laboratory Services Market, by Service Type

  • 8.1. Clinical Exome Sequencing
    • 8.1.1. Adult Exome
    • 8.1.2. Pediatric Exome
  • 8.2. Targeted Gene Panel Testing
    • 8.2.1. Cancer Panels
      • 8.2.1.1. Hematologic Panels
      • 8.2.1.2. Solid Tumor Panels
    • 8.2.2. Cardiovascular Panels
    • 8.2.3. Neurological Disorder Panels
  • 8.3. Whole Genome Sequencing

9. Next Generation Sequencing CLIA Laboratory Services Market, by Application

  • 9.1. Infectious Disease
    • 9.1.1. Bacterial Infections
    • 9.1.2. Viral Infections
  • 9.2. Inherited Disease
    • 9.2.1. Common Disease
    • 9.2.2. Rare Disease
  • 9.3. Oncology
    • 9.3.1. Hematologic Malignancies
    • 9.3.2. Solid Tumor
  • 9.4. Pharmacogenomics
  • 9.5. Reproductive Health
    • 9.5.1. Noninvasive Prenatal Testing
    • 9.5.2. Preimplantation Genetic Testing

10. Next Generation Sequencing CLIA Laboratory Services Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Direct To Consumer Testing
  • 10.3. Hospitals And Clinics
  • 10.4. Research Institutes

11. Next Generation Sequencing CLIA Laboratory Services Market, by Technology Platform

  • 11.1. BGI Sequencing Platforms
    • 11.1.1. Bgiseq 500
    • 11.1.2. Mgiseq
  • 11.2. Illumina Sequencing Platforms
    • 11.2.1. MiSeq
    • 11.2.2. NextSeq
    • 11.2.3. NovaSeq
  • 11.3. Thermo Fisher Sequencing Platforms
    • 11.3.1. Ion Torrent Pgm
    • 11.3.2. Ion Torrent Proton

12. Next Generation Sequencing CLIA Laboratory Services Market, by Sample Type

  • 12.1. Blood
    • 12.1.1. Plasma
    • 12.1.2. Whole Blood
  • 12.2. Saliva
  • 12.3. Tissue
    • 12.3.1. Ffpe
    • 12.3.2. Fresh Frozen

13. Next Generation Sequencing CLIA Laboratory Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next Generation Sequencing CLIA Laboratory Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next Generation Sequencing CLIA Laboratory Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Foundation Medicine, Inc.
    • 16.3.2. Illumina Clinical Services Laboratory, Inc.
    • 16.3.3. Natera, Inc.
    • 16.3.4. Myriad Genetics, Inc.
    • 16.3.5. Fulgent Genetics, Inc.
    • 16.3.6. Guardant Health, Inc.
    • 16.3.7. Invitae Corporation
    • 16.3.8. Veracyte, Inc.
    • 16.3.9. Personalis, Inc.
    • 16.3.10. Adaptive Biotechnologies Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO